Hypertension Diagnostics’ Class A Warrants Declared Effective by SEC

ST. PAUL, MN – August 3, 2000 – Hypertension Diagnostics, Inc. (Nasdaq SmallCap: HDII; HDIIW; HDIIU) today announced that a post-effective amendment to the 1998 initial public offering registration statement registering its Class A Redeemable Warrants has been declared effective by the SEC on August 1, 2000. Pursuant to the terms of the Class A Redeemable Warrants, they may be redeemed by the Company for $.01 per share when the closing bid price of the Company’s common stock exceeds $6.50 per share for 14 consecutive trading days. The Company must provide 30 days prior written notice of such redemption and such written notice must be sent within 10 days of any such 14 consecutive trading day period. The exercise price of the Class A Redeemable Warrants is $5.50 per share. As of August 2, 2000, the Class A Redeemable Warrants are subject to redemption at the election of the Company. The Company has no present intention of exercising its rights to such redemption in the immediate future.

   

 

      
 

   
The Company has also registered 400,000 shares of common stock underlying its 1995 Long-Term Incentive and Stock Option Plan and 750,000 shares of common stock underlying its 1998 Stock Option Plan. Further, pursuant to contractual registration rights, the Company has filed a registration statement seeking to register 1,568,175 shares of its common stock, 1,503,713 of which are shares underlying warrants and options that have not been exercised. Of these shares, 649,257 are subject to lockup restrictions imposed by the State of Minnesota preventing their sale, without the consent of the State of Minnesota, until July 23, 2001.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not predictions of actual future results. Actual results could differ materially from those anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 1999 Annual Report on Form 10-KSB under the caption "Risk Factors", as well as others not now anticipated. These risks and uncertainties include, without limitation, the Company’s ability to receive regulatory approval for its CVProfilor® DO-2020 CardioVascular Profiling System; the availability of third-party reimbursements; and market acceptance of the Company’s products.

Hypertension Diagnostics, CVProfilor® and HDI/PulseWave™ are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Contact: Greg H. Guettler, President

   

Return to the Corporate Pressroom 

   

Back to Top

 

 

 

    

   
     

Copyright © 2010 Hypertension Diagnostics, Inc
To learn more about HDI, email infoteam@hdii.com
Last revised Wednesday June 23, 2010